Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy
Cipolla BG, Mandron E, Lefort JM, Coadou Y, Della Negra E, Corbel L, Le Scodan R, Azzouzi AR, Mottet N
Cancer prevention research (Philadelphia, Pa.) · 96 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2015-05-12 · Cancer Prev Res (Phila) · vol. 8 · número 8 · págs. 712–719
- Editorial
- American Association for Cancer Research
- Citado
- 131 citas · más que el 97% de estudios similares · 5.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 54 trabajos
- Acceso
- De pago
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Estrogen and related hormone effects · Reproductive System and Pregnancy
- Palabras clave
- Sulforaphane, Placebo, Urology, Medicine, Prostate cancer, Prostatectomy, Clinical endpoint, Randomized controlled trial, Placebo-controlled study, Internal medicine, Cancer, Pathology, Double blind
- MeSH
- humans, prostatic neoplasms, neoplasm recurrence, local, postoperative complications, isothiocyanates, sulfoxides, prostate-specific antigen, anticarcinogenic agents, neoplasm staging, prognosis, prostatectomy, follow-up studies, pilot projects, double-blind method, aged, male, neoplasm grading
9 autores
- Bernard G. Cipolla
- E. Mandron
- Jean Marc Lefort
- Yves Coadou🇫🇷Hôpital Saint-Michel
- Emmanuel Della Negra🇫🇷Centre Hospitalier de Saint-Brieuc
- Luc Corbel🇫🇷Centre Hospitalier de Saint-Brieuc
- Ronan Le Scodan🇫🇷Centre Hospitalier privé Saint Grégoire
- Abdel Rahmène Azzouzi🇫🇷Centre Hospitalier Universitaire d'Angers
- Nicolas Mottet🇫🇷Hôpital Nord
Resumen
El texto original del estudio, en el idioma en que se publicó.
Increases in serum levels of prostate-specific antigen (PSA) occur commonly in prostate cancer after radical prostatectomy and are designated "biochemical recurrence." Because the phytochemical sulforaphane has been studied extensively as an anticancer agent, we performed a double-blinded, randomized, placebo-controlled multicenter trial with sulforaphane in 78 patients (mean age, 69 ± 6 years) with increasing PSA levels after radical prostatectomy. Treatment comprised daily oral administration of 60 mg of a stabilized free sulforaphane for 6 months (M0-M6) followed by 2 months without treatment (M6-M8). The study was designed to detect a 0.012 log (ng/mL)/month decrease in the log PSA slope in the sulforaphane group from M0 to M6. The primary endpoint was not reached. For secondary endpoints, median log PSA slopes were consistently lower in sulforaphane-treated men. Mean changes in PSA levels between M6 and M0 were significantly lower in the sulforaphane group (+0.099 ± 0.341 ng/mL) than in placebo (+0.620 ± 1.417 ng/mL; P = 0.0433). PSA doubling time was 86% longer in the sulforaphane than in the placebo group (28.9 and 15.5 months, respectively). PSA increases >20% at M6 were significantly greater in the placebo group (71.8%) than in the sulforaphane group (44.4%); P = 0.0163. Compliance and tolerance were very good. Sulforaphane effects were prominent after 3 months of intervention (M3-M6). After treatment, PSA slopes from M6 to M8 remained the same in the 2 arms. Daily administration of free sulforaphane shows promise in managing biochemical recurrences in prostate cancer after radical prostatectomy.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.